Benzisothiazolinone and Eczema: Why Two Allergy-Trend Studies Should Not Become One Universal Risk

Doctor’s Notes · Eczema Research · November 2026

Benzisothiazolinone, usually shortened to BIT, is a preservative investigated in allergic contact dermatitis. Headlines about a rising allergy trend deserve attention, but a trend in one referral clinic is not a universal probability—and a related preservative's name is not an interchangeable diagnosis.

Two reports, different patterns

A 2025 Danish report followed preservative testing in 6,435 patients during 2014–2023; BIT positivity rose from no more than 0.3% to 5.0%. A separate Belgian report reviewed 6,128 patients during 2010–2022 and found 65 BIT-positive patients overall. Its annual rate rose to 3.72% in 2019 and was 0.71% in 2022. Comparing these results requires attention to the clinic, time window and tested population.

Why annual percentages can tell different stories

People referred for testing are selected because of clinical concerns. Changes in exposure, referrals or testing practice can influence observed rates. The studies were not a head-to-head trial of the same population, nor do they show that the preservative caused every participant's eczema. A local trend should prompt appropriate investigation, not a prediction that a fixed percentage of all product users will become allergic.

Take a work-and-home history seriously

For a painter, cleaner, metalworker or person renovating a home, list relevant products and keep labels and safety data sheets. Bring the task sequence to occupational health if symptoms track work. The objective is to identify actual contact and relevant ingredients, not to assume that every household product contains BIT or that every rash after a project is allergic.

Do not collapse the isothiazolinones into one result

Ask the clinician which specific preservatives were tested and what the results mean for your avoidance list. A prior result to a different substance should be interpreted rather than substituted automatically for a BIT assessment. If changes are advised, ask how to verify product composition and when to review the skin. Specific, documented decisions are more useful than a broad purge based on a trend headline.

For related questions, read our guide to face eczema after painting and our discussion of irritant dermatitis on cleaning day. These address connected care decisions rather than establishing the cause of an individual rash.

Where Dr. Arsy #003 fits

Dr. Arsy #003 offers cosmetic hydration and moisture-barrier support. Check its full current formula against any confirmed preservative allergy before use. It does not prevent sensitization or replace control of a workplace exposure; neither trend study tested #003 or established its suitability for an individual allergic patient.

Workplace dermatitis may also require an epoxy resin, hardener and diluent assessment. For hygiene products, benzalkonium chloride testing illustrates why a striking clinic percentage needs clinical context.

Sources and further reading

1. Primary research record, PubMed
2. Research report and additional evidence
3. NIH MedlinePlus: Contact Dermatitis

Written by the Dr. Arsy Editorial Team for general education, not independent medical review. Discuss diagnosis and treatment with a qualified clinician. #003 is a cosmetic moisturizer, not an eczema medicine. Image is an AI-generated editorial scene using the actual jar as reference. PubMed indexing does not imply NIH endorsement.